Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEWTON: Aflibercept for Macular Edema in CRVO
NCT01870427Phase 4Completed
- Sponsor
- Northern California Retina Vitreous Associates
- Start
- Jun 2013
- Primary completion
- Aug 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in macular edema, sponsored by Northern California Retina Vitreous Associates. Started Jun 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01870427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870427.